Nicox Secures Positive CDE Pre-Submission Feedback, Clearing Path for NCX 470 NDA in China

Sequenced NDA filings across two major regulatory jurisdictions are now in motion for Nicox SA, following positive pre-submission feedback from China's Center for Drug Evaluation (CDE) for NCX 470 (bimatoprost grenod), the company's nitric oxide-donating prostaglandin analogue for open-angle glaucoma and ocular hypertension. China licensee Ocumension Therapeutics considers the feedback sufficient to proceed with a full marketing approval dossier submission to the Chinese National Institutes for Food and Drug Control.

The CDE interaction follows a previously announced successful pre-NDA meeting with the U.S. FDA, positioning Kowa, Nicox's exclusive U.S. partner, to submit the American NDA in summer 2026. The China submission is expected to follow shortly thereafter, a sequencing strategy that compresses the gap between two geographically distinct regulatory clocks without requiring simultaneous dossier readiness.

For regulatory affairs leads tracking parallel submission strategies, the Nicox-Ocumension approach reflects a structured licensing architecture: Kowa holds rights outside China, South Korea, and Southeast Asia, while Ocumension covers those markets. All regulatory and commercialisation costs are borne by the respective licensees, with Nicox eligible to receive milestone payments and royalties on worldwide sales. That cost-allocation model insulates Nicox from direct submission expenditure while preserving its milestone economics across both regulatory pathways.

NCX 470's Phase 3 clinical program in Japan was initiated in summer 2025, adding a third jurisdiction to the asset's global development timeline. QA and regulatory teams at companies managing multi-regional ophthalmology submissions will note that each market, FDA, CDE, and Japan's PMDA, carries distinct dossier requirements, and pre-submission engagement with each agency ahead of formal filing reduces the risk of major deficiency letters that could misalign the sequenced timeline.

The China NDA submission's proximity to the U.S. filing will serve as a near-term indicator of how tightly Ocumension's dossier preparation has tracked Kowa's, and whether the pre-submission feedback from CDE translates into a clean acceptance at the formal review stage.

Source: Nicox SA via GlobeNewswire, 18 June 2026.